86 related articles for article (PubMed ID: 932487)
21. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
22. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
Zuo Z; Tam YK; Diakur J; Wiebe LI
J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo percutaneous absorption of 14C-octamethylcyclotetrasiloxane (14C-D4) and 14C-decamethylcyclopentasiloxane (14C-D5).
Jovanovic ML; McMahon JM; McNett DA; Tobin JM; Plotzke KP
Regul Toxicol Pharmacol; 2008 Mar; 50(2):239-48. PubMed ID: 18178298
[TBL] [Abstract][Full Text] [Related]
24. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl]benzoic acid. 5th communication: factors affecting percutaneous absorption in rats.
Mizojiri K; Okabe H; Sugeno K; Esumi Y; Takaichi M; Okamura Y; Kashiwazaki K; Takahashi N
Arzneimittelforschung; 1997 Mar; 47(3):270-5. PubMed ID: 9105545
[TBL] [Abstract][Full Text] [Related]
25. Nonsteroid antiandrogen inhibiting effect on testosterone metabolism in rat prostate and liver.
Reznikov A; Korpacheva T
Endocrinol Exp; 1990 Dec; 24(4):437-47. PubMed ID: 2096078
[TBL] [Abstract][Full Text] [Related]
26. Concepts and limitations in the application of radiolabeled antiandrogens, estrogens, or androgens as isotopic scanning agents for the prostate.
Berger B; Coffey DS; Scott WW
Invest Urol; 1975 Jul; 13(1):10-6. PubMed ID: 1140914
[TBL] [Abstract][Full Text] [Related]
27. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
28. [Use of the antiandrogen niftolide for studying reserves of the hypothalamo-hypophyseal system in patients with male hypogonadism].
Benikova EA; Reznikov AG; Varga SV; Boiarskaia OIa; Demchenko VN
Probl Endokrinol (Mosk); 1985; 31(3):26-9. PubMed ID: 3932996
[TBL] [Abstract][Full Text] [Related]
29. Effects of a non-steroidal antiandrogen on sexual behavior and pituitary-gonadal function in the male rat.
Södersten P; Gray G; Damassa DA; Smith ER; Davidson JM
Endocrinology; 1975 Dec; 97(6):1468-75. PubMed ID: 1204574
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro skin absorption and metabolism of coumarin (1,2-benzopyrone) in human, rat, and mouse.
Beckley-Kartey SA; Hotchkiss SA; Capel M
Toxicol Appl Pharmacol; 1997 Jul; 145(1):34-42. PubMed ID: 9221821
[TBL] [Abstract][Full Text] [Related]
31. Microbial metabolism. Part 11. Metabolites of flutamide.
Herath W; Khan IA
Chem Pharm Bull (Tokyo); 2010 Apr; 58(4):562-4. PubMed ID: 20410643
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary and percutaneous absorption of 2-propoxyethyl acetate and 2-ethoxyethyl acetate in beagle dogs.
Guest D; Hamilton ML; Deisinger PJ; DiVincenzo GD
Environ Health Perspect; 1984 Aug; 57():177-83. PubMed ID: 6499802
[TBL] [Abstract][Full Text] [Related]
33. Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients.
Goda R; Nagai D; Akiyama Y; Nishikawa K; Ikemoto I; Aizawa Y; Nagata K; Yamazoe Y
Drug Metab Dispos; 2006 May; 34(5):828-35. PubMed ID: 16507648
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of 2-ethyl-1,3-hexanediol. II. Nonsystemic disposition following single percutaneous or peroral doses in Fischer 344 rats.
Frantz SW; Beskitt JL; Grosse CM; Tallant MJ; Ballantyne B
Drug Metab Dispos; 1992; 20(1):6-18. PubMed ID: 1346998
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetics and metabolism of 14C/13C-labeled ortho-phenylphenol formation following dermal application to human volunteers.
Timchalk C; Selim S; Sangha G; Bartels MJ
Hum Exp Toxicol; 1998 Aug; 17(8):411-7. PubMed ID: 9756132
[TBL] [Abstract][Full Text] [Related]
36. In vitro percutaneous absorption of [14C] ethylene glycol.
Driver J; Tardiff RG; Sedik L; Wester RC; Maibach HI
J Expo Anal Environ Epidemiol; 1993; 3(3):277-84. PubMed ID: 8260837
[TBL] [Abstract][Full Text] [Related]
37. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
[TBL] [Abstract][Full Text] [Related]
38. Metabolism of 14C-labeled doxylamine succinate (Bendectin) in the rhesus monkey (Macaca mulatta).
Slikker W; Holder CL; Lipe GW; Korfmacher WA; Thompson HC; Bailey JR
J Anal Toxicol; 1986; 10(3):87-92. PubMed ID: 2873269
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism.
Wester RC; Noonan PK; Smeach S; Kosobud L
J Pharm Sci; 1983 Jul; 72(7):745-8. PubMed ID: 6411893
[TBL] [Abstract][Full Text] [Related]
40. Absorption, disposition kinetics, and metabolic pathways of cyclohexene oxide in the male Fischer 344 rat and female B6C3F1 mouse.
Sauer JM; Bao J; Smith RL; McClure TD; Mayersohn M; Pillai U; Cunningham ML; Sipes IG
Drug Metab Dispos; 1997 Mar; 25(3):371-8. PubMed ID: 9172957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
